Oncopeptides AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-249.59	-284.61	-249.11	-337.95	-1,430
Depreciation & Amortization	-	9.75	11.04	16.84	14.57
Other Amortization	-	-	-	0.32	0.42
Asset Writedown & Restructuring Costs	-	-	-	-	16.59
Stock-Based Compensation	-	10.91	11.5	14.81	14.54
Other Operating Activities	12.72	6.06	4.14	-3.84	-94.11
Change in Accounts Receivable	-	-4.3	-16.02	53.17	24.66
Change in Inventory	-	-1.95	-2.42	-1.46	-0.32
Change in Accounts Payable	-	3.15	-13.19	-22.89	-104.91
Change in Other Net Operating Assets	20.37	0.42	-25.42	-139.52	42.49
Operating Cash Flow	-216.49	-260.57	-279.49	-420.51	-1,516
Capital Expenditures	-	-0.36	-0.12	-2.51	-0.34
Investment in Securities	-	0.85	-0	-	-
Other Investing Activities	-	0	0	-	-
Investing Cash Flow	-	0.5	-0.12	-2.51	-0.34
Long-Term Debt Repaid	-	-8.03	-9.14	-15.54	-15.41
Net Debt Issued (Repaid)	-	-8.03	-9.14	-15.54	-15.41
Issuance of Common Stock	-	313.48	116.02	436.02	1,116
Other Financing Activities	122.16	-41.64	-	-28.07	-67.05
Financing Cash Flow	122.16	263.81	106.89	392.4	1,034
Foreign Exchange Rate Adjustments	-1.95	1.39	1.61	12.94	4.63
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-0
Net Cash Flow	-96.28	5.13	-171.11	-17.67	-478.07
Free Cash Flow	-216.49	-260.93	-279.61	-423.02	-1,517
Free Cash Flow Margin	-304.41%	-824.47%	-793.89%	-5063.03%	-1282.16%
Free Cash Flow Per Share	-0.95	-1.57	-3.09	-5.14	-20.14
Cash Interest Paid	-	0	0.57	0.88	0.95
Cash Income Tax Paid	0.11	-0.59	-1.65	0.04	12.22
Levered Free Cash Flow	-156.64	-169.03	-191.36	-289.31	-1,086
Unlevered Free Cash Flow	-141.94	-161.12	-187.74	-288.76	-1,086
Change in Working Capital	20.37	-2.68	-57.06	-110.69	-38.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.